231 related articles for article (PubMed ID: 34092725)
1. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract][Full Text] [Related]
3. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
4. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
5. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.
Suwa S; Tomita R; Kataoka K; Ueno S
Ocul Immunol Inflamm; 2022 Aug; 30(6):1522-1526. PubMed ID: 33797309
[TBL] [Abstract][Full Text] [Related]
6. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
Czichos C; Wawrzynów B; Chamalis C; von Jagow B
Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
[No Abstract] [Full Text] [Related]
7. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
8. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
[No Abstract] [Full Text] [Related]
9. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
11. BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION MISTAKEN FOR NIVOLUMAB-INDUCED VOGT-KOYANAGI-HARADA DISEASE-LIKE SYNDROME.
Dallinga MG; Bolhuis K; Bins A; de Hoog J
Retin Cases Brief Rep; 2024 May; 18(3):332-336. PubMed ID: 36728009
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
13. Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report.
Koyama M; Nishijima E; Honda T; Gonmori-Ohta C; Sasamoto T; Tanaka K; Watanabe A; Nakano T; Akiyama M
BMC Ophthalmol; 2024 Mar; 24(1):115. PubMed ID: 38481205
[TBL] [Abstract][Full Text] [Related]
14. A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.
Minami K; Egawa M; Kajita K; Murao F; Mitamura Y
Case Rep Ophthalmol; 2021; 12(3):952-960. PubMed ID: 35082654
[TBL] [Abstract][Full Text] [Related]
15. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
17. NIVOLUMAB-INDUCED HARADA-LIKE UVEITIS WITH BACILLARY DETACHMENT MIMICKING CHOROIDAL METASTASIS.
Ng CC; Ng JC; Johnson RN; McDonald HR; Agarwal A
Retin Cases Brief Rep; 2023 May; 17(3):233-238. PubMed ID: 34027908
[TBL] [Abstract][Full Text] [Related]
18. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
